Astellas announced that the FDA has accepted for review the company’s New Drug Application (NDA) for tacrolimus extended-release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients. Tacrolimus extended-release capsules are a once daily formulation of the calcineurin inhibitor immunosuppressant tacrolimus (Prograf; Astellas).
The NDA submission is based on six randomized and comparative studies of 2,842 (1,689 tacrolimus extended-release) kidney transplant recipients and 689 (393 tacrolimus extended-release) liver transplant recipients. Astellas also has more than five years of follow-up patient data from the treatment of transplant recipients with tacrolimus extended-release capsules.
For more information call (800) 727-7003 or visit www.us.astellas.com.